Assessment of needs for plasma for fractionation in Europe

Biologicals

Volumn 27, Issue 4, 1999, Pages 337-341

  Burckhardt, Johann J ^a  

^a Central Laboratory in Bern   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DETERGENT; IMMUNOGLOBULIN; SOLVENT; VIRUS RNA;

BLOOD COMPONENT; BLOOD DONOR; CONFERENCE PAPER; EUROPE; FRACTIONATION; HEMOPHILIA; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; NUCLEIC ACID ANALYSIS; PARVOVIRUS; PLASMA; PRIORITY JOURNAL; PROBABILITY; RECIPIENT; RISK BENEFIT ANALYSIS; SAFETY; VACCINATION; VIRUS INACTIVATION; VIRUS INFECTION;

B19 VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; PARVOVIRUS;

EID: 0033501990     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1999.0229     Document Type: Conference Paper

References (20)

1. Yu MW, Mason BL, Tankersley DL. Detection and characterization of hepatitis C virus RNA in immune globulins. Transfusion. 34:1994;596-602.
2. James RC, Mosley JW. Hepatitis C virus transmission by intravenous immunoglobulin. Lancet. 346:1995;374.
3. Yu MW, Finlayson JS, Tankersly D. Hepatitis C virus transmission by intravenous immunoglobulin. Lancet. 346:1995;374-375.
4. Smith DB, Lawlor E, Power J. A second outbreak of Hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sang. 76:1999;175-180.
5. Lawlor E, Power J, Garson JA. Transmission rates of Hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. Vox Sang. 76:1999;138-143.
6. Quality and safety of plasma products, Brussels, 27 September 1994.
7. Committee for Proprietary Medicinal Products, Note for guidance on plasma-derived medicinal products, CPMP/BWP/269/95, EMEA, 1998.
8. Committee for Proprietary Medicinal Products, Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/BWP/268/95, EMEA, 1998.
9. Committee for Proprietary Medicinal Products, Addendum to note for guidance on plasma-derived medicinal products. The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools, CPMP/BWP/390/97, EMEA, 1998.
10. Robertson BH, Alter MJ, Bell BP. Hepatitis A virus sequences detected in clotting factor concentrates associated with disease transmission. Biologicals. 26:1998;95-99.
11. Chudy M, Budek I, Keller-Stanislawski B. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol. 57:1999;91-99.
12. Burckhardt JJ, Bachmann P, Bauerfeind U. How much might the genome-amplification-testing reduce the probability of window donations in Switzerland? XXVth Congress of the International Society of Blood Transfusion (ISBT), Oslo, Norway, June 27-July 2, 1998. Vox Sang. 74:1998;1103.
13. Lelie PN, Cuypers HTM, Reesink HW. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol. 37:1992;203-209.
14. Schreiber GB, Busch MP, Kleinman SH. The risk of transfusion-transmitted viral infections. N Engl J Med. 334:1996;1685-1690.
15. Müller-Breitkreuz, K, EPFA Working Group on Quality Assurance, Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997, Vox Sang.
16. Kempf, C. Viral safety of Albumin SRC, HAEMO, April 1997.
17. Kempf C, Morgenthaler J-J, Rentsch M. Viral safety and manufacturing of an intravenous immunoglobulin. Kazatchkine MD, Morell A. Intravenous Immunoglobulin Research and Therapy. 1996;11-18 The Parthenon Publishing Group, New York, London.
18. Foster PR. Assessment of the potential of plasma fractionation process to remove causative agentss of transmissible spongiform encephalopathy. Transfusion Med. 9:1999;3-14.
19. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol. 93:1996;714-719.
20. Hilfenhaus J, Groner A, Nowak T. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion. 37:1997;935-940.